Public overview — you're viewing Whitespace from outside the app. Sign in with an approved account to open it.Sign in →

Portfolio Strategy & Clinical Trial Intelligence

Decision-grade clinical white space — in days, not quarters.

Target uncrowded indications before committing clinical capital.

The platform biopharma leaders use to de-risk indication expansion, in-licensing, and pipeline strategy. Whitespace synthesizes live global trial registries and treatment paradigms to identify crowded indications, unmet needs, and high-conviction clinical white space with line-by-line auditability.

See the executive briefs Initiate an assessment

New to Whitespace? Read how it works

Auditable trial & guideline provenance (NCT and guideline citations)
Multi-dimensional white space scoring (crowding, mechanism, feasibility)
Treatment paradigm alignment (ESMO, NCCN and published standard-of-care lines of therapy)
Board-ready strategic readouts across oncology, neurology, immunology and rare diseases

Competitive density by line of therapy and modality — illustrative

Small moleculeBiologicCell / geneDeviceCombination

First lineopenopen

Later linesopen

Maintenanceopenopenopen

Early diseaseopenopenopenopen

Crowded — trials already running Whitespace — little or nothing yet

Illustrative. Each assessment builds its own map from live trials, assets and combinations.

The Three Strategic Bottlenecks in Indication Planning

“The $250k consultant deck was obsolete before the steering committee met.”

Static snapshots leave leadership blind when competitor trials read out.

“Registry data is a noisy haystack without clinical context.”

ClinicalTrials.gov lists trials without lines of therapy, biomarker segments or guideline status.

“Portfolio expansion decisions still rely on lagging retrospectives.”

Deal teams wait months for scenario analyses that should take 48 hours.

One platform, three mandates

The same assessments serve the decision, the analysis behind it, and the evidence that has to survive an Investment Committee.

For the C-suite and portfolio leadership

Executive Readouts

Board-ready one-page decision briefs — strategic whitespace, competitive density, and opportunity rankings.

For strategy, BD&L and analytics teams

Indication Evaluation Engine

End-to-end 8-stage portfolio assessment — from disease scoping and regimen mapping to composite opportunity scoring.

For Medical Affairs and CI

Clinical Evidence & Governance

Expert review console for Medical Affairs and CI teams to verify treatment paradigms, asset aliases, and guideline citations.

Latest Indication Assessments

Live from your portfolio. Open any assessment for its executive brief.

Indication Portfolio

Built for Investment Committees, Corporate Development, and Medical Affairs

Live registry synchronization

Assessments read the current registry record, not last quarter's export.

Deterministic scoring

Every score is produced by a stated framework with weighted, anchored criteria.

Zero synthetic data

Nothing seeded, nothing invented — every figure traces to a named record.

Access restricted to approved accounts

Only invited leadership and team members can open the portfolio.